A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.

Authors :: Richardson, Paul G.
Amatangelo, Michael
Berenson, James R.
Cerchione, Claudio
Dimopoulos, Meletios A.
Toftmann Hansen, Charlotte
Hwang, Soo Jeong
Koo, Phillip
Kuroda, Junya
Oriol, Albert
Orlowski, Robert Z.
Quach, Hang
Raab, Marc S.
Rocci, Alberto
Wang, Yue
White, Darrell
Yu, Brian
Zhou, Zehua
Katz, Jessica
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS8070-TPS8070, 1p
Publication Year :: 2023

Full Text Access

Tools